JP5368092B2 - ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法 - Google Patents

ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法 Download PDF

Info

Publication number
JP5368092B2
JP5368092B2 JP2008525664A JP2008525664A JP5368092B2 JP 5368092 B2 JP5368092 B2 JP 5368092B2 JP 2008525664 A JP2008525664 A JP 2008525664A JP 2008525664 A JP2008525664 A JP 2008525664A JP 5368092 B2 JP5368092 B2 JP 5368092B2
Authority
JP
Japan
Prior art keywords
group
substituted
alkyl
individually
rifamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008525664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009505974A (ja
JP2009505974A5 (enExample
Inventor
ローズ，ヤニック，ステファン
シブラ，ステファン
カン，ティン
ファー，アデル ラファイ
ディートリッヒ，エヴェリン
ラフォンティーヌ，ヤニック
レディ，ランガ
Original Assignee
ターガンタ セラピュティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターガンタ セラピュティクス，インコーポレイティド filed Critical ターガンタ セラピュティクス，インコーポレイティド
Publication of JP2009505974A publication Critical patent/JP2009505974A/ja
Publication of JP2009505974A5 publication Critical patent/JP2009505974A5/ja
Application granted granted Critical
Publication of JP5368092B2 publication Critical patent/JP5368092B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008525664A 2005-08-11 2006-08-11 ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法 Expired - Fee Related JP5368092B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70714505P 2005-08-11 2005-08-11
US60/707,145 2005-08-11
PCT/IB2006/004128 WO2007096703A2 (en) 2005-08-11 2006-08-11 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections

Publications (3)

Publication Number Publication Date
JP2009505974A JP2009505974A (ja) 2009-02-12
JP2009505974A5 JP2009505974A5 (enExample) 2011-11-24
JP5368092B2 true JP5368092B2 (ja) 2013-12-18

Family

ID=38437733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008525664A Expired - Fee Related JP5368092B2 (ja) 2005-08-11 2006-08-11 ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法

Country Status (11)

Country Link
US (1) US8404664B2 (enExample)
EP (1) EP1928890B1 (enExample)
JP (1) JP5368092B2 (enExample)
KR (1) KR101327635B1 (enExample)
CN (1) CN101282981B (enExample)
AU (1) AU2006339058B2 (enExample)
BR (1) BRPI0614758A2 (enExample)
CA (1) CA2618741C (enExample)
EA (1) EA016059B1 (enExample)
IL (1) IL189270A (enExample)
WO (1) WO2007096703A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
EP2324041A4 (en) 2008-08-13 2012-06-13 Targanta Therapeutics Corp PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
CN103501819B (zh) 2011-02-24 2016-08-17 Ktb肿瘤研究有限责任公司 二膦酸盐-前药
FR2973378B1 (fr) * 2011-03-28 2013-10-04 Atlanthera Derives d'acide hydroxybisphosphonique bifonctionnels
MX369022B (es) * 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
MX2017007231A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
WO2016090038A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
CN104524928A (zh) * 2014-12-30 2015-04-22 上海锅炉厂有限公司 一种捕集二氧化碳的吸收剂
CN107011380A (zh) * 2016-01-28 2017-08-04 臧伟 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用
EP3645539B1 (en) * 2017-06-26 2021-04-07 Biofer S.p.A. Pyrido-imidazo rifamycin derivatives as antibacterial agent
WO2020014269A1 (en) * 2018-07-09 2020-01-16 Biovinc, Llc. Bisphosphonate quinolone conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR208F (enExample) 1964-07-31
US4261891A (en) 1965-08-24 1981-04-14 Ciba-Geigy Corporation Antibiotically active rifamycin derivatives
GB1478563A (en) 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
IT1056272B (it) 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
AU536524B2 (en) * 1979-06-28 1984-05-10 Gruppo Lepetit S.P.A. Water soluble hydrozones of 3-formylifamyan
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP2746041B2 (ja) * 1992-02-14 1998-04-28 三菱化学株式会社 新規なステロイド誘導体
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
JPH093080A (ja) * 1995-04-21 1997-01-07 Sumitomo Pharmaceut Co Ltd 新規な骨親和性エストロゲン誘導体
US5880111A (en) 1995-06-07 1999-03-09 Farcasiu; Dan Therapeutic derivations of diphosphonates
CA2267984A1 (en) * 1996-10-09 1998-04-16 Elizanor Biopharmaceuticals, Inc. Diphosphonate therapeutic compounds
PE20020044A1 (es) 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
EP1511753A4 (en) 2001-09-06 2005-10-12 Activbiotics Inc ANTIMICROBIAL MEDIUM AND ITS USE
US7122525B2 (en) 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
WO2003051299A2 (en) 2001-12-13 2003-06-26 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
CN1894259A (zh) 2003-08-22 2007-01-10 活跃生物工艺学公司 利福霉素类似物及其应用
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
WO2005070940A2 (en) 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
US7238694B2 (en) 2004-01-13 2007-07-03 Cumbre Pharmaceuticals, Inc. Rifamycin imino derivatives effective against drug-resistant microbes
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7256187B2 (en) 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7250413B2 (en) 2004-04-26 2007-07-31 Cumbre Pharmaceuticals Inc. C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
US7202246B2 (en) 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
JP5236944B2 (ja) 2004-07-22 2013-07-17 カムブァ、アイピー、ヴェンチュァズ、エル、ピー 微生物感染を治療するためのリファマイシン誘導体

Also Published As

Publication number Publication date
AU2006339058B2 (en) 2012-09-06
KR101327635B1 (ko) 2013-11-12
CA2618741A1 (en) 2007-08-30
CA2618741C (en) 2014-03-25
IL189270A0 (en) 2008-08-07
CN101282981B (zh) 2012-09-26
US20110263534A1 (en) 2011-10-27
KR20080035687A (ko) 2008-04-23
US8404664B2 (en) 2013-03-26
EP1928890B1 (en) 2013-04-03
EP1928890A2 (en) 2008-06-11
WO2007096703A2 (en) 2007-08-30
IL189270A (en) 2015-05-31
WO2007096703A3 (en) 2008-01-03
EA016059B1 (ru) 2012-01-30
EA200800570A1 (ru) 2009-02-27
JP2009505974A (ja) 2009-02-12
AU2006339058A1 (en) 2007-08-30
CN101282981A (zh) 2008-10-08
BRPI0614758A2 (pt) 2011-04-12
EP1928890A4 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
US8524691B2 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
JP5368092B2 (ja) ホスホン化リファマイシン類および骨と関節感染の予防と治療のためのその投与法
HUP9902636A2 (hu) NAALADáz inhibtor hatású foszfinil-származékok és ezeket tartalmazó gyógyszerkészítmények
US8946144B2 (en) Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
IE914388A1 (en) Novel methylenebisphosphonic acid derivatives
WO2007138381A2 (en) Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
OA11730A (en) Organo-phosphorus compounds and their utilization.
US20080287396A1 (en) Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections
OA11803A (en) Organophosphorous compounds and the use thereof.
EP0971939B1 (en) Bis-phosphonate conjugates with alkylating moieties having antitumor activity
IL113246A (en) Bisphosphonates and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120814

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130912

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees